{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:22Z","timestamp":1794272242315,"version":"4.9.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104719","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:51:04Z","timestamp":1785696664000},"page":"104719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor hypoxia: Molecular pathways and therapeutic interventions"],"prefix":"10.1016","volume":"31","author":[{"given":"Jie-Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-1467","authenticated-orcid":false,"given":"Pai-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104719_b0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104719_b0010","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.7150\/thno.84947","article-title":"Visualizing vasculature and its response to therapy in the tumor microenvironment","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104719_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211036304","article-title":"Hypoxia and the tumor microenvironment","volume":"20","author":"Li","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.drudis.2026.104719_b0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10555-022-10067-x","article-title":"Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry","volume":"41","author":"Andreucci","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2026.104719_b0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104719_b0030","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","article-title":"Acidity generated by the tumor microenvironment drives local invasion","volume":"73","author":"Estrella","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","article-title":"Hypoxia signaling in human health and diseases: implications and prospects for therapeutics","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104719_b0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00018-024-05537-0","article-title":"HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects","volume":"82","author":"Shi","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104719_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI134813","article-title":"The 2019 Nobel Prize honors fundamental discoveries in hypoxia response","volume":"130","author":"Moslehi","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104719_b0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104719_b0065","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3892\/mmr.2015.3689","article-title":"Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (Review)","volume":"12","author":"Yang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2026.104719_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102551","article-title":"Roles of hypoxia-inducible factor-prolyl hydroxylases in aging and disease","volume":"102","author":"Galkin","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.drudis.2026.104719_b0075","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104719_b0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-2952(99)00292-0","article-title":"Expression of hypoxia-inducible factor 1: mechanisms and consequences","volume":"59","author":"Semenza","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104719_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J Physiol"},{"key":"10.1016\/j.drudis.2026.104719_b0090","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1038\/s41467-024-53593-8","article-title":"HIF1\u03b1-regulated glycolysis promotes activation-induced cell death and IFN-\u03b3 induction in hypoxic T cells","volume":"15","author":"Shen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104719_b0095","first-page":"6669","article-title":"HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors","volume":"61","author":"Sowter","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0100","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00018-019-03039-y","article-title":"Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria","volume":"76","author":"Thomas","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0105","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104719_b0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI89212","article-title":"HIF-1\u03b1 promotes autophagic proteolysis of Dicer and enhances tumor metastasis","volume":"128","author":"Lai","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104719_b0115","doi-asserted-by":"crossref","first-page":"11806","DOI":"10.1093\/nar\/gkae792","article-title":"A transcription-independent role for HIF-1\u03b1 in modulating microprocessor assembly","volume":"52","author":"Li","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104719_b0120","doi-asserted-by":"crossref","first-page":"ra10","DOI":"10.1126\/scisignal.2003417","article-title":"A nontranscriptional role for HIF-1\u03b1 as a direct inhibitor of DNA replication","volume":"6","author":"Hubbi","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2026.104719_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cmet.2005.05.001","article-title":"Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing","volume":"1","author":"Guzy","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2026.104719_b0130","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cmet.2011.10.008","article-title":"Induction of the mitochondrial NDUFA4L2 protein by HIF-1\u03b1 decreases oxygen consumption by inhibiting complex I activity","volume":"14","author":"Tello","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2026.104719_b0135","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2026.104719_b0140","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/MCB.05124-11","article-title":"Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels","volume":"31","author":"Mungai","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104719_b0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104719_b0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13046-020-01824-3","article-title":"Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons","volume":"40","author":"Akman","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/boc.201800050","article-title":"The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance","volume":"111","author":"Madden","year":"2019","journal-title":"Biol Cell"},{"key":"10.1016\/j.drudis.2026.104719_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.005","article-title":"Epigenetic remodelling under hypoxia","volume":"98","author":"Verdikt","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104719_b0165","doi-asserted-by":"crossref","first-page":"L1096","DOI":"10.1152\/ajplung.00325.2017","article-title":"Epigenetic changes by DNA methylation in chronic and intermittent hypoxia","volume":"313","author":"Nanduri","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.drudis.2026.104719_b0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1549-8719.2011.00154.x","article-title":"miR-210: the master hypoxamir","volume":"19","author":"Chan","year":"2012","journal-title":"Microcirculation"},{"key":"10.1016\/j.drudis.2026.104719_b0175","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104719_b0180","first-page":"9158","article-title":"Interactions between hypoxia-inducible factor-1\u03b1 and other molecules in cancer: a literature review","volume":"12","author":"Sun","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.drudis.2026.104719_b0185","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2026.104719_b0190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104719_b0195","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/neuonc\/now258","article-title":"Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells","volume":"19","author":"Colwell","year":"2017","journal-title":"Neuro Onco"},{"key":"10.1016\/j.drudis.2026.104719_b0200","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2353\/ajpath.2010.091021","article-title":"Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres","volume":"177","author":"Bar","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2026.104719_b0205","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104719_b0210","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3748\/wjg.v20.i9.2237","article-title":"Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies","volume":"20","author":"Rucki","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2026.104719_b0215","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2217\/fon.13.92","article-title":"Role of hypoxia-inducible factors in breast cancer metastasis","volume":"9","author":"Gilkes","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0220","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1158\/1541-7786.MCR-18-0345","article-title":"Molecular portrait of hypoxia in breast cancer: a prognostic signature and novel HIF-regulated genes","volume":"16","author":"Ye","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0225","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/ijms17071061","article-title":"Schlaepfer IR Aberrant lipid metabolism promotes prostate cancer: role in cell survival under hypoxia and extracellular vesicles biogenesis","volume":"17","author":"Deep","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0230","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.humpath.2008.02.013","article-title":"Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas","volume":"39","author":"Furlan","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.drudis.2026.104719_b0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbrc.2019.07.039","article-title":"EZH2 regulates PD-L1 expression via HIF-1\u03b1 in non-small cell lung cancer cells","volume":"517","author":"Zhao","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104719_b0240","doi-asserted-by":"crossref","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.drudis.2026.104719_b0245","article-title":"Defining hypoxia in cancer: a landmark evaluation of hypoxia gene expression signatures","volume":"5","author":"Di Giovannantonio","year":"2025","journal-title":"Cell Genom"},{"key":"10.1016\/j.drudis.2026.104719_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1055062","article-title":"Advances in PET and MRI imaging of tumor hypoxia","volume":"10","author":"Gouel","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104719_b0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2023.09.002","article-title":"Targeting intratumoral hypoxia to enhance anti-tumor immunity","volume":"96","author":"Semenza","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104719_b0260","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231106","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Oteiza","year":"2025","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2026.104719_b0265","doi-asserted-by":"crossref","first-page":"138","DOI":"10.21147\/j.issn.1000-9604.2024.02.04","article-title":"Hypoxic tumor microenvironment: destroyer of natural killer cell function","volume":"36","author":"Zhang","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4143\/crt.2025.200","article-title":"Understanding immune cell adaptation to tumor hypoxia for maximized therapeutic efficacy of immunotherapy: biology and non-invasive imaging application","volume":"58","author":"Oh","year":"2026","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.drudis.2026.104719_b0275","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104719_b0280","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drudis.2026.104719_b0285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0290","first-page":"62","article-title":"Hypoxia-activated prodrugs and (lack of) clinical progress: the need for hypoxia-based biomarker patient selection in phase III clinical trials","volume":"15","author":"Spiegelberg","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0295","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.7150\/ijbs.92211","article-title":"Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma","volume":"20","author":"Wang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0300","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","article-title":"Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104","volume":"13","author":"Patterson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0305","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3324\/haematol.2014.118455","article-title":"Phase I\/II study of the hypoxia-activated prodrug PR104 in refractory\/relapsed acute myeloid leukemia and acute lymphoblastic leukemia","volume":"100","author":"Konopleva","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2026.104719_b0310","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0315","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1158\/1078-0432.CCR-10-1439","article-title":"Pharmacokinetic\/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors","volume":"16","author":"Hicks","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0320","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/acsmedchemlett.3c00321","article-title":"Design and biological evaluation of piperazine-bearing nitrobenzamide hypoxia\/GDEPT prodrugs: the discovery of CP-506","volume":"14","author":"Ashoorzadeh","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104719_b0325","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1259\/0007-1285-59-708-1238","article-title":"A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069","volume":"59","author":"Horwich","year":"1986","journal-title":"Br J Radiol"},{"key":"10.1016\/j.drudis.2026.104719_b0330","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2026.104719_b0335","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/molecules24081559","article-title":"Studies towards hypoxia-activated prodrugs of PARP inhibitors","volume":"24","author":"Dickson","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104719_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108521","article-title":"Potential targeting of the tumor microenvironment to improve cancer virotherapy","volume":"250","author":"Liao","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104719_b0345","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.drudis.2021.07.014","article-title":"Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer","volume":"26","author":"Liao","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104719_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101582","article-title":"An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy","volume":"46","author":"Tseng","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.drudis.2026.104719_b0355","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104719_b0360","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid cardiovascular response to belzutifan in HIF2A-mediated paraganglioma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104719_b0365","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","article-title":"Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy","volume":"58","author":"Yu","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.drudis.2026.104719_b0370","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104719_b0375","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/annonc\/mdw188","article-title":"Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial","volume":"27","author":"Keefe","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0380","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104719_b0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1752-8062.2011.00376.x","article-title":"Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors","volume":"5","author":"Gayed","year":"2012","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0390","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1021\/acsptsci.3c00296","article-title":"Digoxin-mediated inhibition of potential hypoxia-related angiogenic repair in modulated electro-hyperthermia (mEHT)-treated murine triple-negative breast cancer model","volume":"7","author":"Bokhari","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2026.104719_b0395","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3727\/096504014X13983417587366","article-title":"HIF-1 dimerization inhibitor acriflavine enhances antitumor activity of sunitinib in breast cancer model","volume":"22","author":"Yin","year":"2015","journal-title":"Oncol Res"},{"key":"10.1016\/j.drudis.2026.104719_b0400","first-page":"10084","article-title":"Acriflavine enhances the antitumor activity of the chemotherapeutic drug 5-fluorouracil in colorectal cancer cells","volume":"15","author":"Zargar","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2026.104719_b0405","doi-asserted-by":"crossref","first-page":"12653","DOI":"10.1038\/s41598-017-12929-9","article-title":"Low-dose YC-1 combined with glucose and insulin selectively induces apoptosis in hypoxic gastric carcinoma cells by inhibiting anaerobic glycolysis","volume":"7","author":"Wakiyama","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104719_b0410","first-page":"255","article-title":"A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent","volume":"29","author":"Kim","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00109-013-1102-5","article-title":"Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer","volume":"92","author":"Xiang","year":"2014","journal-title":"J Mol Med"},{"key":"10.1016\/j.drudis.2026.104719_b0420","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.19.00816","article-title":"Randomized phase III study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small-cell lung cancer (GALAXY-2)","volume":"38","author":"Pillai","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0425","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s12276-022-00812-1","article-title":"Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation","volume":"54","author":"Kim","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2026.104719_b0430","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s11658-020-00212-1","article-title":"Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia","volume":"25","author":"Bartoszewska","year":"2020","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.drudis.2026.104719_b0435","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00262-025-04067-3","article-title":"HIF-PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2026.104719_b0440","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309957121","article-title":"Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment","volume":"121","author":"Ma","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104719_b0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1021\/acs.jmedchem.4c01698","article-title":"Discovery of ZG-2305, an orally bioavailable factor inhibiting HIF inhibitor for the treatment of obesity and fatty liver disease","volume":"68","author":"Wu","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104719_b0450","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1021\/acs.jmedchem.1c00415","article-title":"Inhibition of the oxygen-sensing asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor: a potential hypoxia response modulating strategy","volume":"64","author":"Wu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104719_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527835","article-title":"Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia","volume":"9","author":"Li","year":"2023","journal-title":"Kidney Dis"},{"key":"10.1016\/j.drudis.2026.104719_b0460","first-page":"134","article-title":"Efficacy and safety of roxadustat for anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, open-label, active-controlled phase III study","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0465","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ajh.26865","article-title":"Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies","volume":"98","author":"Glaspy","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.drudis.2026.104719_b0470","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.molcel.2019.09.019","article-title":"KDM3A senses oxygen availability to regulate PGC-1\u03b1-mediated mitochondrial biogenesis","volume":"76","author":"Qian","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104719_b0475","doi-asserted-by":"crossref","first-page":"33110","DOI":"10.18632\/oncotarget.26011","article-title":"The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth","volume":"9","author":"Parrish","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104719_b0480","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1158\/1535-7163.MCT-20-0328","article-title":"IOX1 suppresses wnt target gene transcription and colorectal cancer tumorigenesis through inhibition of KDM3 histone demethylases","volume":"20","author":"Hoyle","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104719_b0485","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","article-title":"Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma","volume":"25","author":"Katagi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104719_b0490","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/2767-9764.CRC-24-0296","article-title":"Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomas","volume":"5","author":"Rask","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.drudis.2026.104719_b0495","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2021.39.15_suppl.3080","article-title":"A phase 1\/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors","volume":"39","author":"Gabrail","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104719_b0500","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2020.08.028","article-title":"Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation\/chemotherapy in vivo","volume":"494","author":"Le Reste","year":"2020","journal-title":"Cancer Lett"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:45:22Z","timestamp":1790095522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001248"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104719","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor hypoxia: Molecular pathways and therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104719"}}